ChemoCentryx to Participate in Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.
- MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.
- Replays of both the J.P. Morgan and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.
- Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).
- ChemoCentryxalso has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.